Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: In hyponatremic patients, concurrent dialysate flow during hemodialysis may be an ideal option to mitigate complications such as osmotic demyelination syndrome (ODS).
Methods: Present randomized controlled trial enrolled dialysis-requiring chronic kidney disease (CKD) and acute kidney injury (AKI) patients with serum sodium levels < 125 mEq/L during January 2020 over 16 months. Hemodynamically unstable patients, as well as those with a history of seizures and neurological conditions, were excluded. All were randomized to concurrent and countercurrent dialysate flow groups during two-h dialysis session. Hydration status was evaluated by Body Composition Monitor BCMTM and hourly sodium was estimated to guide ultrafiltration. Comparative analysis of sodium correction rates (meq/L/h) during dialysis, neurological deterioration via Mini-Mental State Examination (MMSE) scores, and ODS during 1 week and 1 month in both groups was done. Two-way repeated measures ANOVA was used to compare sodium correction trends.
Results: A total of 44 hyponatremic patients of AKI (17.39%), CKD (56.52%) and acute on CKD (26.09%) were randomized to concurrent (n = 23) and countercurrent (n = 21) dialysate groups. Postdialysis sodium correction rate was nonsignificantly slower in the concurrent group (45.45%) vs. the countercurrent group (36.36% group, p = 0.44). Neurological deterioration, measured via MMSE scores, and ODS incidence were absent in both groups. The concurrent group exhibited a higher proportion of patients without neurological deterioration (73.91%) compared to the countercurrent group (57.14%, p = 0.241). Comparable survival between the two groups was seen at 10, 20, and 30 days. No significant risk factors for mortality were identified in either group.
Conclusion: Concurrent dialysate flow demonstrates a slower but nonsignificant rate of sodium correction, making it a safer alternative for managing severe hyponatremia during hemodialysis by reducing the risk of rapid neurological shifts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/sdi.70008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing Concurrent and Countercurrent Dialysate Flow in Hemodialysis: A Pilot Study on Hyponatremic Patients.
Semin Dial
September 2025
Department of Nephrology, Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital, New Delhi, India.
Background: In hyponatremic patients, concurrent dialysate flow during hemodialysis may be an ideal option to mitigate complications such as osmotic demyelination syndrome (ODS).
Methods: Present randomized controlled trial enrolled dialysis-requiring chronic kidney disease (CKD) and acute kidney injury (AKI) patients with serum sodium levels < 125 mEq/L during January 2020 over 16 months. Hemodynamically unstable patients, as well as those with a history of seizures and neurological conditions, were excluded.
Design Parametrization of Central Venous Catheters for Pediatric Dialysis: Supporting the Quest for the Most Influential Features.
ASAIO J
September 2025
Department of Nephrology, Great Ormond Street Hospital for Children, London, United Kingdom.
Pediatric hemodialysis is a life-saving treatment for children with chronic kidney diseases. Central venous catheters (CVCs) are the most commonly used vascular access, despite being commonly subject to complications leading to inadequate hemodialysis and catheter replacement. The available CVCs feature various design elements reflecting ongoing efforts to achieve optimal performance.
View Article and Find Full Text PDFIntroduction: Renal artery stenosis (RAS) reduces renal blood flow and activates the renin-angiotensin-aldosterone (RAA) system, resulting in renovascular hypertension (RVH).
Case Presentation: We report a case of a 49-year-old woman with RVH due to bilateral renal artery stenosis, predominantly on the right. Despite pharmacological treatment, blood pressure remained poorly controlled; leading to severe heart failure that required dialysis.
Dialysis Disequilibrium Syndrome and Severe Metabolic Acidosis: A Fatal Case.
Cureus
August 2025
Internal Medicine, East Carolina University Brody School of Medicine, Greenville, USA.
Dialysis disequilibrium syndrome (DDS) is a rare but potentially fatal complication of renal replacement therapy, typically characterized by cerebral edema and often precipitated by the rapid correction of severe azotemia. Clinical symptoms are often non-specific, and, in some cases, the condition can be fatal. While the role of azotemia in DDS is well established, alternative mechanisms, such as the brain acidosis paradox, have also been proposed.
View Article and Find Full Text PDFEngineering the Future of Stem Cells in Vascular Reconstruction: A Leap Towards Functional Endothelialized Tissue-Engineered Vascular Conduits.
Stem Cell Rev Rep
September 2025
Paris Cité University, INSERM UMR-S 970, Paris Cardiovascular Research Centre, Paris, France.
The transition from reconstructive to regenerative strategies in vascular surgery has intensified the need for grafts that are biocompatible, growth-capable, and resistant to thrombosis. Addressing this challenge, Park et al. introduce a groundbreaking method for engineering fully biological, endothelialized tissue-engineered vascular conduits (TEVCs) using decellularized human umbilical arteries (dHUAs) coated with human induced pluripotent stem cell-derived endothelial cells (hiPSC-ECs).
View Article and Find Full Text PDF